Ray E. Peck
Chief Executive Officer
With over 25 years’ experience in front line business development, as well as sales management, Ray has worked in over a dozen countries, and on almost every continent. He is multi-lingual, and has worked with Global “Big Pharma” clients, as well as with the entrepreneurs at small virtual companies. He has held positions of increasing responsibility including Director of North American and European – Pharma/Biotech Business Development, Director of Global Strategic Accounts at Azopharma, Executive Director at CoreRx Pharma Services, and most recently as Founder and CEO of CRO Solutions. Ray’s focus has been in drug development services from discovery chemistry, to clinical trial materials, and to niche commercial manufacturing, including both small molecule and large molecule programs. Ray founded CRO Solutions/VxP Biologics in 2010, which has since grown to include contract labs on several continents, and in almost every area of drug development. Ray holds a BS from Michigan State.
Chief Financial Officer
Ms. Keepper has over 25 years’ experience in management, accounting and finance. She received her BS in Accounting and Finance from Lipscomb University in Nashville, TN, and went on to earn her CPA. Kim spent seven years at KPMG, where she served in multiple roles, including Audit Manager over several large publicly traded companies. Kim spent four years in Japan working on the AAFES Management Team, and continued on for three years in positions of increasing responsibility in the United States. In 2002, Kim joined Renal Care Group, a kidney dialysis company, as Regional Controller. In 2008, Kim became Revenue Controller at Fresenius Medical Care, the largest kidney dialysis company in the United States, and one of the largest in the world. Kim has served as our Chief Financial Officer since 2010.
Patti Day, BSN RN CCRC
Director of Operations
Patti brings 15 years of clinical trial experience from both the corporate and academic sectors. She has managed investigational drug trials in a variety of therapeutic areas, including dermatology, immunology, rheumatology, endocrinology, and oncology. She received her BSN from Indiana University in 2001. Her research career began as a coordinator at Indiana University School of Medicine. She then moved to the private sector to focus on project management, effectively earning her Lean Six Sigma Yellow Belt for Public Health from Purdue HealthcareTAP in 2011. Patti earned her certification as a Clinical Research Professional from ACRP in 2013. Through her site-level work on various novel therapies for chemotherapy-induced anemia, small cell lung cancer, mesothelioma, psoriasis and atopic dermatitis, she has built strong relationships with numerous pharmaceutical and CRO partners. In December, 2014, she became Director of Research at Dawes Fretzin Clinical Research Group where she was responsible for the successful execution of over 50 industry-sponsored, Phase IIa-IV trials. Patti joined VxP in March of 2016.
Executive Director of Business Development
Teresa began her career with Schering Plough’s R&D Group as an analytical chemist, followed by a position with Oclassen Pharmaceuticals as Laboratory Supervisor, Quality Assurance and Project Management. In 1991, she moved to Cellegy Pharmaceuticals as Manager of Analytical Services, followed by Dow Pharmaceutical Sciences in Petaluma, CA, in 1994 as their first Project Manager. In 1998, Teresa moved to BioMarin Pharmaceuticals to develop their Program Management group. Teresa was responsible for six drug development programs there and played a significant role in the development and commercialization of BioMarin’s first two lead commercial drug products; Aldurazyme® and Naglazyme®. In 2002, Teresa transitioned to Business Development with Dow Pharmaceutical Sciences to build their first Business Development group. Notable success with that endeavor led to the West Coast Business Development Director position for Azopharma in 2007. In November 2007, with 25+ years of experience, Teresa launched Business Development Connections (BDC), which provides business development support to service providers for the life sciences industry. Teresa joined VxP Biologics in October of 2013.
Ann Newman, PhD.
Senior Scientific Advisor
Dr. Ann Newman is currently a pharmaceutical consultant at Seventh Street Development Group with over 20 years of large pharma and contract research experience. Dr. Newman received her PhD in Chemistry from the University of Connecticut. For ten years, Dr. Newman performed characterization studies on a wide range of pharmaceutical systems at Bristol-Meyers Squibb, covering drug substance and product scale-up from late drug discovery to launch and manufacturing. After that she was Vice President of Materials Science at SSCI, Inc. overseeing characterization of API and drug product samples, crystallization and polymorph screens, salt and cocrystal selections, quantitative assays, amorphous projects, and problem solving for the pharmaceutical industry. As Vice President of Research and Development at Aptuit, she instituted a companywide R&D initiative over six global sites and covering areas such as API, preclinical (toxicology, safety, pharmacokinetics), formulation, solids, analytical, clinical packaging, and regulatory. She holds an adjunct faculty position in Industrial and Physical Pharmacy at Purdue University and is a collaborator on over 40 publications and over 75 technical presentations.